Growth Hormone · 5mg × 10 vials
In plain terms: Tesamorelin is a research compound - oral, fast-acting and well studied.
Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH(1-44)). It binds the GHRH receptor on the anterior pituitary and triggers pulsatile release of the body's own growth hormone, which in turn raises circulating IGF-1. The key engineering trick is an N-terminal trans-3-hexenoyl modification that protects the molecule from dipeptidyl peptidase IV degradation, giving it enough plasma stability to actually reach the pituitary (native GHRH has a half-life of a couple minutes; tesamorelin's plasma half-life is around 26 minutes, longer in HIV patients). Because it works upstream of the pituitary rather than replacing GH directly like exogenous HGH does, tesamorelin preserves the body's natural feedback loop (IGF-1 negative feedback still throttles output), which is why side-effect profile is cleaner than HGH and why visceral fat is selectively burned without wrecking subcutaneous fat or muscle. The downstream effect is that hepatic and visceral adipose tissue (the dangerous deep belly fat that wraps organs) becomes the preferred fuel substrate, with mean VAT reductions of 15-18% over 26 weeks in pivotal trials.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
Trial protocol used 2 mg daily from day one in HIV patients, but for non-HIV research the 1 mg start is the community standard. It cuts the early water retention and tingling/numbness signal in half. Reconstitute 10 mg vial with 2 ml BAC = 5 mg/ml, so 1 mg = 0.20 ml = 20 IU on a U-100 syringe. Inject subQ into the lower abdomen pre-bed.
Most users hit their peak visceral fat response at 2 mg daily over 16-26 weeks. Above 2 mg there's no efficacy data and the IGF-1 elevation becomes harder to keep in physiological range. If joint pain or carpal tunnel symptoms emerge, pull back to 1 mg rather than stopping cold.
Bodybuilders and AAS users running tesa specifically for "HGH gut" / palumboism reversal often pair with low-dose HGH (1-2 IU) at the same pre-bed window. Monitor IGF-1 quarterly if running long-term, target middle to upper end of age-adjusted normal range, pull back if it crests above the reference range. Watch for HbA1c drift on a 12-month run, the pivotal data shows a small +0.1% bump that can compound on top of GLP-1 stacks.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://www.nejm.org/doi/full/10.1056/NEJMoa072375) - landmark pivotal trial, 412 patients, 15-18% VAT reduction at 26 weeks on 2 mg/day SC
Read study ↗PubMedFalutz et al, 2010 - randomized trial with safety extension (PMID 20101189)](https://pubmed.ncbi.nlm.nih.gov/20101189/) - 52-week safety/efficacy data
Read study ↗PubMedFalutz et al, 2010 - pooled Phase 3 analysis (PMID 20554713)](https://pubmed.ncbi.nlm.nih.gov/20554713/) - combined two Phase 3 trials, AE rates and IGF-1 data
Read study ↗PubMedStanley et al, Lancet HIV 2019 - Tesamorelin on NAFLD in HIV32% liver fat reduction at 12 months, fibrosis prevention
Read study ↗PubMedStanley et al, JCI Insight 2020 - hepatic transcriptomic effectsmechanism of liver fat reduction
Read study ↗PubMedReduction in visceral adiposity associated with improved metabolic profile (PMID 22495074)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3348954/) - metabolic profile improvements paralleling VAT loss
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Water retention / "puffy face" weeks 1-2: most-reported sensation, resolves by week 3-4 as body adapts
Numbness/tingling in fingers (mild carpal-tunnel-like): common at 2 mg, resolves on 1 mg dose drop
Joint stiffness in the morning: reported across forums, especially in users running tesa with HGH or CJC+Ipa
Vivid dreams / improved sleep: positive AE, very commonly reported because the GH pulse hits during sleep
Hunger increase: tesa doesn't suppress appetite (unlike GLP-1s), and the GH pulse can mildly elevate hunger; some users report stronger appetite at the 2 mg dose
Belly measurement drop before scale weight drop: classic visceral-specific signal, users report waistline tightening at 6-8 weeks before total weight moves
Route: SubQ
Injection site: abdomen, rotate within the abdominal panel daily to avoid injection site reactions (this is the most common AE in the Phase 3 trials)
Storage: refrigerated, 28 days after reconstitution. Unreconstituted vials refrigerated (lyophilized form is more forgiving but keep cold).
Notes: Inject pre-bed on an empty stomach (2-3 hours post-meal). Eating right before/after blunts the GH pulse because insulin suppresses GH release. Pre-bed timing also stacks with the body's natural overnight GH pulse for an amplified effect. Do not shake the vial, swirl gently to mix. Allow vial to reach room temp before injecting once mixed. Use a fresh insulin syringe per draw.